Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: A retrospective study

Cancer

Volumn 116, Issue 13, 2010, Pages 3143-3151

  Kaufman, Jonathan L ^a   Nooka, Ajay ^a   Vrana, Mark ^b   Gleason, Charise ^a   Heffner, L Thompson ^a   Lonial, Sagar ^a  

^a EMORY UNIVERSITY   (United States)

^b Northeast Georgia Cancer Care   (United States)

Author keywords

Bortezomib; Induction; Multiple myeloma; Stem cell transplantation; Thalidomide

Indexed keywords

BORTEZOMIB; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; THALIDOMIDE;

ADULT; AGED; AGITATION; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLEEDING; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CONSTIPATION; COUGHING; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; FEVER; GASTRITIS; HEADACHE; HERPES ZOSTER; HUMAN; INSOMNIA; LEG EDEMA; LIMB PAIN; LUNG EMBOLISM; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE CRAMP; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; RETROSPECTIVE STUDY; SIDE EFFECT; STEM CELL MOBILIZATION; SYMPTOM; THROMBOCYTOPENIA; TREATMENT RESPONSE; TREMOR; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; COMBINED MODALITY THERAPY; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOADJUVANT THERAPY; PYRAZINES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; THALIDOMIDE; TIME FACTORS;

EID: 77954304370     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25143     Document Type: Article

References (48)

1. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood. 2008;111:2521-2526.
2. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516-2520.
3. Lonial S, Cavenagh J. Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma. Br J Haematol. 2009;145:681-708.
4. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906-917.
5. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006;24:431-436.
6. Rajkumar SV, Rosinol L, Hussein M, et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol. 2008;26:2171-2177.
7. Richardson PG, Mitsiades C, Schlossman R, et al. Bortezomib in the front-line treatment of multiple myeloma. Expert Rev Anticancer Ther. 2008;8:1053-1072.
8. van de Velde H, Liu X, Chen G, Cakana A, Deraedt W, Bayssas M. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica. 2007;92:1399-1406. (Pubitemid 350144158)
9. Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002;99:4525-4530. (Pubitemid 34627223)
10. Borrello I, Ferguson A, Huff CA, et al. Bortezomib and thalidomide treatment of newly diagnosed patients with multiple myeloma: efficacy and neurotoxicity [abstract]. Blood (ASH Annual Meeting Abstracts). 2006;108. Abstract 3528.
11. Chen S, Jiang B, Qiu L, Yu L, Zhong Y, Gao W. Bortezomib plus thalidomide treatment of newly diagnosed patients with multiple myeloma - efficacy and neurotoxicity: results of a multicenter study [abstract]. Blood (ASH Annual Meeting Abstracts). 2007;110. Abstract 3600.
12. Pineda-Roman M, Zangari M, van Rhee F, et al. VTD combination therapy with bortezomib-thalidomidedexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia. 2008;22:1419-1427. (Pubitemid 352006086)
13. Cavo M, Tacchetti P, Patriarca F, et al. Superior complete response rate and progression-free survival after autologous transplantation with up-front Velcade-thalidomide-dexamethasone compared with thalidomide-dexamethasone in newly diagnosed multiple myeloma [abstract]. Blood (ASH Annual Meeting Abstracts). 2008;112. Abstract 158.
14. Drach J, Odelga V, Ackermann J, et al. VTD (Velcade, thalidomide, dexamethason) represents an active induction regimen for patients with multiple myeloma. Haematologica. 2008;93:87-88.
15. Giralt S, Thandi R, Qazilbash M, et al. Retrospective comparison of transplant outcomes in patients with multiple myeloma according to induction therapy with thalidomide/dexamethasone (TD) with or without bortezomib (VTD) [abstract]. Blood (ASH Annual Meeting Abstracts). 2007;110. Abstract 948.
16. Wang M, Han XH, Zhang L, et al. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia. 2008;22:179-185.
17. Yoon SS, Kim HJ, Lee DS, et al. Sequential VAD (vincristine, Adriamycin, dexamethasone) and VTD (bortezomib, thalidomide, dexamethasone) induction followed by highdose therapy with autologous stem cell transplantation and maintenance treatment with bortezomib for newly diagnosed multiple myeloma. Interim results of phase II trial. Haematologica. 2008;93:86-87.
18. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Multiple Myeloma (version 1.2009). Fort Washington, Pa: National Comprehensive Cancer Network; 2008.
19. Gladney SP, Lonial S, Kaufman JL. Multiple myeloma presenting with advanced renal failure: a case report and new treatment options. Clin Lymphoma Myeloma. 2008;8:52-54. (Pubitemid 351449719)
20. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102:1115-1123.
21. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467-1473.
22. Cavo M, Tosi P, Zamagni E, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol. 2007;25:2434-2441.
23. Harousseau J-L, Attal M, Moreau P, Garban F, Facon T, Avet-Loiseau H. The prognostic impact of complete remission (CR) plus very good partial remission (VGPR) in a double-transplantation program for newly diagnosed multiple myeloma (MM): combined results of the IFM 99 trials [abstract]. Blood (ASH Annual Meeting Abstracts). 2006;108. Abstract 3077.
24. O'Shea D, Giles C, Terpos E, et al. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. Bone Marrow Transplant. 2006;37:731-737.
25. Wang M, Delasalle K, Thomas S, Giralt S, Alexanian R. Complete remission represents the major surrogate marker of long survival in multiple myeloma [abstract]. Blood (ASH Annual Meeting Abstracts). 2006;108. Abstract 403.
26. Hussein MA, Baz R, Srkalovic G, et al. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma. Mayo Clin Proc. 2006;81:889-895.
27. Wang M, Giralt S, Handy B, et al. Complete remission and survival in multiple myeloma [abstract]. J Clin Oncol. 2008;26. Abstract 8523.
28. Ladetto M, Pagliano G, Avonto I, et al. Consolidation with bortezomib, thalidomide and dexamethasone induces molecular remissions in autografted multiple myeloma patients [abstract]. Blood (ASH Annual Meeting Abstracts). 2007;110. Abstract 530.
29. Bensinger W. Stem-cell transplantation for multiple myeloma in the era of novel drugs. J Clin Oncol. 2008;26:480-492. (Pubitemid 351171703)
30. Davies FE, Forsyth PD, Rawstron AC, et al. The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma. Br J Haematol. 2001;112:814-819.
31. Paiva B, Vidriales MB, Cervero J, et al. Multiparameter flow cytometry remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood. 2008;112:4017-4023.
32. Rawstron AC, Davies FE, DasGupta R, et al. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood. 2002;100:3095-3100.
33. Barlogie B, Pineda-Roman M, van RF, et al. Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood. 2008;112:3115-3121.
34. Zangari M, van RF, Anaissie E, et al. Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy. Br J Haematol. 2008;141:433-444. (Pubitemid 351550542)
35. Wang M, Giralt S, Delasalle K, Handy B, Alexanian R. Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology. 2007;12:235-239. (Pubitemid 46930250)
36. Corso A, Barbarano L, Mangiacavalli S, et al. Bortezomib with high-dose dexamethasone as first line therapy in patients with multiple myeloma candidates to high-dose therapy [abstract]. Blood (ASH Annual Meeting Abstracts). 2007;110. Abstract 3595.
37. Harousseau J-L, Attal M, Leleu X, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica. 2006;91:1498-1505.
38. Harousseau JL, Mathiot C, Attal M, et al. Bortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantation (ASCT) in previously untreated multiple myeloma (MM): updated data from IFM 2005/01 trial [abstract]. J Clin Oncol. 2008;26. Abstract 8505.
39. Jagannath S, Durie BGM, Wolf JL, et al. Long-term follow-up of patients treated with bortezomib alone and in combination with dexamethasone as frontline therapy for multiple myeloma [abstract]. Blood (ASH Annual Meeting Abstracts). 2006;108. Abstract 796.
40. Richardson P, Lonial S, Jakubowiak A, et al. Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma: encouraging efficacy in high risk groups with updated results of a phase I/II study [abstract]. Blood (ASH Annual Meeting Abstracts). 2008;112. Abstract 92.
41. Wang M, Delasalle K, Giralt S, Alexanian R. Rapid control of previously untreated multiple myeloma with bortezomiblenalidomide- dexamethasone (BLD) [abstract]. Blood (ASH Annual Meeting Abstracts). 2007;110. Abstract 3611.
42. Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006;24:3113-3120.
43. Richardson PG, Sonneveld P, Schuster MW, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol. 2009;144:895-903.
44. Mileshkin L, Stark R, Day B, Seymour JF, Zeldis JB, Prince HM. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol. 2006;24:4507-4514. (Pubitemid 46630990)
45. Richardson P, Schlossman R, Jagannath S, et al. Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc. 2004;79:875-882.
46. Plasmati R, Pastorelli F, Cavo M, et al. Neuropathy in multiple myeloma treated with thalidomide: a prospective study. Neurology. 2007;69:573-581. (Pubitemid 47357264)
47. Zangari M, Elice F, Fink L, Tricot G. Thrombosis in multiple myeloma. Expert Rev Anticancer Ther. 2007;7:307-315.
48. Lonial S, Richardson PG, San MJ, et al. Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. Br J Haematol. 2008;143:222-229.